Illumina shares are trading lower after the company provided preliminary Q4 and FY24 financial results and FY25 guidance.
ILMNJanuary 14, 2025
Read more →Illumina Announces Preliminary Financials For Q4 2024 With $1.10B Revenue, 2024 Revenue At $4.33B, GAAP EPS $5.65-$5.67; Non-GAAP EPS $4.12-$4.14; Sees 2025 Revenue Outlook Of $4.28B-$4.4B, Non-GAAP Margin 23%, EPS Growth 10%
ILMNJanuary 14, 2025
Read more →Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?
ILMNNvidia is making an ambitious leap into leveraging AI and accelerated computing to transform healthcare solutions.
January 14, 2025
Read more →Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $150
ILMNJanuary 13, 2025
Read more →Illumina, NVIDIA To Collaborate To 'Decode Biology And Propel Precision Health;' Illumina Shares Spike Higher
ILMNJanuary 13, 2025
Read more →How Is The Market Feeling About Illumina?
ILMNDecember 25, 2024
Read more →Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
ILMNDecember 24, 2024
Read more →Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
ILMNNovember 20, 2024
Read more →Illumina Highlights TruSight Oncology Portfolio
ILMNNovember 19, 2024
Read more →Baird Maintains Neutral on Illumina, Raises Price Target to $139
ILMNNovember 6, 2024
Read more →TD Cowen Maintains Buy on Illumina, Raises Price Target to $177
ILMNNovember 5, 2024
Read more →UBS Maintains Neutral on Illumina, Raises Price Target to $145
ILMNNovember 5, 2024
Read more →RBC Capital Maintains Outperform on Illumina, Raises Price Target to $254
ILMNNovember 5, 2024
Read more →JP Morgan Maintains Neutral on Illumina, Raises Price Target to $140
ILMNNovember 5, 2024
Read more →Citigroup Maintains Buy on Illumina, Raises Price Target to $190
ILMNNovember 5, 2024
Read more →Barclays Maintains Equal-Weight on Illumina, Raises Price Target to $145
ILMNNovember 5, 2024
Read more →Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $145
ILMNNovember 5, 2024
Read more →Illumina Raises FY2024 Adj EPS Guidance from $3.80-3.95 to $4.05-4.15 vs $3.82 Est; Narrows FY2024 Sales Guidance from $4.30B-4.35B to $4.30B vs $4.35B Est
ILMNNovember 4, 2024
Read more →Illumina Sees Q4 Sales $1.070B vs $1.08B Est
ILMNNovember 4, 2024
Read more →Illumina Q3 2024 Adj. EPS $1.14 Beats $0.88 Estimate, Sales $1.080B Beat $1.079B Estimate
ILMNNovember 4, 2024
Read more →Looking Into Illumina's Recent Short Interest
ILMNNovember 4, 2024
Read more →Illumina Announces That It Will Present Updates On Several Key Innovations In Whole-Genome Sequencing, Proteomics, And Single-Cell Technology At The American Society Of Human Genetics Annual Meeting
ILMNOctober 31, 2024
Read more →